Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Neurogastroenterology tests factor in avoidant/restrictive food intake disorder

23 Nov 2019

Patients undergoing neurogastroenterology examinations commonly present with symptoms of avoidant/restrictive food intake disorder (ARFID) driven mostly by fear of gastrointestinal symptoms, as shown in a recent study.

Researchers retrospectively examined the medical records of 410 consecutive individuals referred (aged 18–90 years; 73.0 percent female) to a tertiary care centre for neurogastroenterology examination.

Twenty-six individuals (6.3 percent) met the full criteria for ARFID, while 71 (17.3 percent) had clinically significant avoidant or restrictive eating behaviours but insufficient information for a definitive ARFID diagnosis.

Most of the patients with ARFID symptoms (90/97; 92.8 percent) endorsed fear of gastrointestinal symptoms as motivation for their avoidant or restrictive eating.

Binary logistic regressions showed that likelihood of having ARFID symptoms was significantly high in patients with eating- or weight-related complaints (odds ratio [OR], 5.09, 95 percent confidence interval [CI], 2.54–10.21); those presenting with dyspepsia, nausea or vomiting (OR, 3.59, 95 percent CI, 2.04–6.32); those with abdominal pain (OR, 4.72, 95 percent CI, 1.87–11.81); and those with more than one diagnosis of a gastrointestinal disorder (OR, 1.63, 95 percent CI, 1.26–2.10).

“ARFID is a feeding and eating disorder that is characterized by avoidant or restrictive eating not primarily motivated by body shape or weight concerns,” according to the researchers. The present data highlight the importance of evaluating patients undergoing neurogastroenterology or motility examinations for symptoms of ARFID.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.